170 results on '"Kobayashi, Kokoro"'
Search Results
2. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
3. Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)
4. Oxidative DNA damage: Induction by fructose, in vitro, and its enhancement by hydrogen peroxide
5. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
6. Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study
7. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial
8. Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study
9. Assessment of a cancer genomic profile test for patients with metastatic breast cancer
10. Evaluation of Secure Pad Resilient to Shoulder Hacking
11. Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial
12. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer
13. Oxidative DNA damage: induction by fructose, in vitro, and its enhancement by hydrogen peroxide
14. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
15. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
16. Evaluation of Secure Pad Resilient to Shoulder Hacking
17. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
18. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience
19. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer
20. Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice
21. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial
22. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
23. Decreased hormonal sensitivity after childbirth rather than the tumor size influences the prognosis of very young breast cancer patients
24. Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
25. Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: a propensity score-adjusted analysis of a prospective cohort study
26. Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)
27. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort
28. Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice.
29. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer
30. Abstract P1-15-02: Low incidence of hepatitis B reactivation after chemotherapy in Japanese breast cancer patients with resolved HBV
31. Prognostic significance of histological therapeutic effect in preoperative chemotherapy for breast cancer
32. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
33. Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer
34. Initial assessment of a cancer genomic profile test for patients with metastatic breast cancer: a retrospective study
35. Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients
36. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab
37. Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial
38. MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer
39. A Series of PIN/Password Input Methods Resilient to Shoulder Hacking Based on Cognitive Difficulty of Tracing Multiple Key Movements
40. Abstract P3-14-02: A cohort study to evaluate the efficacy and safety of postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT-cohort study)
41. Abstract OT2-02-07: Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)
42. Abstract P5-01-15: Monitoring of CDK4/6 inhibitor treatment response through blood liquid biopsy in metastatic breast cancer
43. Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy
44. Clinical introduction of Microsatellite instability (MSI) test for the Solid Tumors at a single institute
45. Characteristics and prognosis of leptomeningeal metastasis in patients with breast cancer
46. Liquid biopsy for detection of actionable mutation in various cancer patients
47. Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
48. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
49. Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial (RESPECT).
50. Differences of TILs, hormone receptor, and HER2 status between primary and metastatic tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.